Basiliximab in the treatment of acute steroid-resistant rejection after liver transplantation;Basiliximab en el tratamiento del rechazo celular agudo resistente a los corticoides postrasplante hepático

Gastroenterologia y Hepatologia

Volumn 35, Issue 9, 2012, Pages 649-651

  Alvarez Castro, Ana M ^a   Seijo Ríos, Susana ^a   Molina Pérez, Esther ^a   Castroagudín, Javier F ^a   Varo Pérez, Evaristo ^a  

^a University Hospital of Santiago de Compostela   (Spain)

Author keywords

Acute steroid resistant rejection; Basiliximab; Liver transplantation

Indexed keywords

BASILIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CANCER STAGING; DRUG TREATMENT FAILURE; EARLY CANCER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; CYCLOSPORINE; DRUG RESISTANCE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER FUNCTION TESTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYCOPHENOLIC ACID; PREGNENEDIONES; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; TACROLIMUS;

EID: 84868560151     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2012.03.016     Document Type: Article

References (12)

1. Castroagudín J.F., Molina E., Varo E. Calcineurin inhibitors in liver transplantation: to be or not to be. Transplant Proc 2011, 43:2220-2223.
2. Neuberger J. Incidence, timing, and risk factors for acute and chronic rejection. Liver Transpl Surg 1999, 5:S30-S36.
3. Bartlett A.S., Ramadas R., Furness S., Gane E., McCall J.L. The natural history of acute histologic rejection without biochemical graft dysfunction in orthotopic liver transplantation: a systematic review. Liver Transpl 2002, 8:1147-1153.
4. Solomon H., Gonwa T.A., Mor E., Holman M.J., Gibbs J., Watemberg I., et al. OKT3 rescue for steroid-resistant rejection in adult liver transplantation. Transplantation 1993, 55:87-91.
5. Bijleveld C.G., Klompmaker I.J., van der Ber A.P., Gouw A.S., Hepkema B.G., Haagsma E.B., et al. Incidence, risk factors, and outcome of antithymocyte globulin treatement of steroid-resistant rejection after liver transplantation. Transpl Int 1996, 9:570-575.
6. Ramirez C.B., Doria C., di Francesco F., Iaria M., Kang Y., Marino I.R. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months. J Surg Res 2007, 138:198-204.
7. Neuhaus P., Clavien P.A., Kittur D., Salizzoni M., Rimola A., Abeywickrama K., et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002, 8:132-142.
8. Varo E., López A., Castroagudín J.F., Delgado M., Conde R., Ferrer E., et al. Alternative immunosupression for acute renal failure in liver transplantation: role of ultra-low tacrolimus and basiliximab. Transplant Proc 2002, 34:1567-1568.
9. Chariat M.N., Erren M., Chariat M., Deng M., Wolters H.H., Dietl K.H. Basiliximab in the therapy of acute rejection after organ transplantation. Transplant Proc 2001, 33:2380.
10. Fernandes M.L., Lee Y.M., Sujedja D., Wai C.T., Isaac J., Prabhakaran K., et al. Wai CT Treatment of steroid-resistant acute liver transplant rejection with basiliximab. Transplant Proc 2005, 37:2179-2180.
11. Orr D.W., Portmann B.C., Knisely A.S., Stoll S., Rela M., Muiesan P., et al. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation. Transplant Proc 2005, 37:4373-4379.
12. Aw M.M., Taylor R.M., Verma A., Parke A., Baker A.J., Hadzic D., et al. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transplant recipients: a preliminary experience. Transplantation 2003, 75:796-799.